I'm LongbridgeAI, I can summarize articles.TARS.US closed at $90.78 this week, up 26.51%. Over the same period the S&P 500 gained just 0.09%, leaving TARS about 26.42 percentage points ahead of the benchmark. The stock gapped up from $71.47 on Monday (31 Aug), eased to $74.05 on Tuesday, then accelerated through Wednesday and Thursday on heavier volume. Friday peaked at $91.53 intraday before settling at $90.78, with the week’s range spanning 29.13%.
The Week
TARS.US closed at $90.78 this week, up 26.51%. Over the same period the S&P 500 gained just 0.09%, leaving TARS about 26.42 percentage points ahead of the benchmark. The stock gapped up from $71.47 on Monday (31 Aug), eased to $74.05 on Tuesday, then accelerated through Wednesday and Thursday on heavier volume. Friday peaked at $91.53 intraday before settling at $90.78, with the week’s range spanning 29.13%.
Key Events
The flagship corporate development landed on Friday, when Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals, extending its position in eye care. Earlier in the week, the company said it would attend the Wells Fargo Healthcare Conference and take part in a series of upcoming investor meetings. On Thursday, CMO Elizabeth Yeu disclosed the sale of $787,879.86 in ordinary shares; the stock still closed higher that day and advanced further on Friday. TARS also appeared among the top ten US gainers mid-week.
Analyst Ratings
Eight analysts currently cover TARS, all rating it buy with no holds, underweights or sells. The consensus rating is strong buy, with a consensus target price of $94, about 3.5% above the current $90.78. Individual targets range from $84 to $104, a gap of roughly $20 that shows some disagreement at the top end. Within the pharmaceuticals sector, TARS ranks 65th out of 205 names.
The Week Ahead
Macro data dominates the coming week. NFIB small-business optimism lands on Tuesday 8 Sep, followed on Thursday 10 Sep by initial jobless claims, producer price readings and existing-home sales, alongside a 10-year Treasury auction. TARS has no scheduled earnings release next week; the focus shifts to integration updates from the Alkeus deal and any new details out of the investor meetings.
In Short
This week’s rally tracked a material acquisition and a tightly grouped buy consensus, with volume expanding alongside the move. Valuation sits at a negative P/E and roughly 11.5x book, while the latest trading day showed small and medium-sized money on the inflow side. The tension between near-term momentum and an as-yet unprofitable earnings base hinges on how quickly the Alkeus integration and pipeline progress translate into fundamentals.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.